Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Applicable disease and eligible for myeloablative SCT~* Patients must have two partially HLA-matched CBUs~* Back-up stem cell source~* Adequate Karnofsky Performance score or Lansky Play-Performance scale~* Sufficient physiological reserves~* Signed written informed consent~Exclusion Criteria:~* HLA-matched related donor able to donate~* Prior allogeneic HSCT~* Lymphoma patients with progressive disease~* Other active malignancy~* Human immunodeficiency virus (HIV) infection~* Active or uncontrolled infection~* Active/symptoms of central nervous system (CNS) disease~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NiCord (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).